Ratings Hikal Limited NSE India S.E.

Equities

Market Closed - NSE India S.E. Other stock markets 03:02:05 2024-05-18 EDT			5-day change	1st Jan Change
298.6 ^INR	+0.22%		+6.43%	-1.76%

05-09	Transcript : Hikal Limited, Q4 2024 Earnings Call, May 09, 2024
05-09	Hikal Limited Recommends Finally Dividend for the Financial Year 2023-2024	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

With an expected P/E ratio at 54.24 and 35.51 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.

	1st Jan change	Capi.	ESG Refinitiv
HIKAL LIMITED	-1.76%	442M	-
ELI LILLY AND COMPANY	+34.35%	693B	C+
NOVO NORDISK A/S	+29.39%	584B	B
JOHNSON & JOHNSON	-3.49%	372B	C+
MERCK & CO., INC.	+20.15%	332B	B-
ABBVIE INC.	+6.19%	294B	C+
ASTRAZENECA PLC	+14.11%	239B	B+
ROCHE HOLDING AG	-3.03%	211B	A+
NOVARTIS AG	+10.02%	210B	B-
AMGEN INC.	+9.21%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality